Neurocrine: Q3 Earnings Snapshot
Published . Updated .
Covered by 2 outlets: KVUE, KTVB.
This report does not map to a usual set of affected companies.
Directly affected
- NBIX Neurocrine Biosciences
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Neurocrine Biosciences belongs to, so it often moves with news about it.
- BNTX BioNTech SE-10.1% 15d
BioNTech SE is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- QGEN Qiagen N.V
Qiagen N.V is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- CRSP CRISPR Therapeutics AG-10.4% 30d
CRISPR Therapeutics AG is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+18.4% 30d
Amgen is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.7% 30d
Gilead Sciences is a peer of Neurocrine Biosciences in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NBIXNo price data for this ticker | — | — | — | — | — | — | — |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| BNTXNo price data for this ticker | — | — | — | — | — | — | — |
| QGENNo price data for this ticker | — | — | — | — | — | — | — |
| CRSPNo price data for this ticker | — | — | — | — | — | — | — |
| AMGNNo price data for this ticker | — | — | — | — | — | — | — |
| GILDNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Neurocrine: Q3 Earnings Snapshot KVUE
Source: KVUE
Congressional trades in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 83 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Neurocrine: Q3 Earnings Snapshot” looks
25 out of 100
“Neurocrine: Q3 Earnings Snapshot” scores 25 out of 100. The score uses 2 sources.